Standout Papers

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial 2022 2026 2023 2024148
  1. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial (2022)
    John A. Spertus, Mary C. Birmingham et al. Nature Medicine

Citation Impact

3 from Science/Nature 66 standout
Sub-graph 1 of 22

Citing Papers

Spatially organized cellular communities form the developing human heart
2024 StandoutNature
Inhibition of fatty acid oxidation enables heart regeneration in adult mice
2023 StandoutNature
2 intermediate papers

Works of David E. Lanfear being referenced

Single-Cell RNA Sequencing of the Cardiovascular System: New Looks for Old Diseases
2019
Genetic Variation in the B-Type Natiuretic Peptide Pathway Affects BNP Levels
2007

Author Peers

Author CCM Surgery Biomedical Engineering Last Decade Papers Cites
David E. Lanfear 1796 1188 871 176 4.2k
Shagufta U. Patel 1 1 130 10 358
Susan L. McCammon 16 3 1 24 769
Selvinaz Dalaklıoğlu 46 24 4 21 372
L. Rosén 36 21 7 15 635
John Mudrick 1 49 18 472

All Works

Loading papers...

Rankless by CCL
2026